Botulinum toxin for myofascial pain syndromes in adults

Soares, Adriana; Andriolo, Régis B; Atallah, Álvaro Nagib; Silva, Edina MK da

doi:10.1002/14651858.cd007533

Cited by 13 publications

(14 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We recently reported a case of non-odontogenic toothache in which the patient's masseteric muscle tenderness was relieved after a BoNT injection [39]. Several systematic reviews and trials using BoNT to treat myofascial pain in other regions of the body have been reported [40][41][42]. BoNT injections alleviate pain by suppressing muscular contractions and preventing the release of acetylcholine [42].…”

Section: Myofascial Painmentioning

confidence: 99%

“…Several systematic reviews and trials using BoNT to treat myofascial pain in other regions of the body have been reported [40][41][42]. BoNT injections alleviate pain by suppressing muscular contractions and preventing the release of acetylcholine [42]. However, no previous randomized clinical trials have confirmed the effective treatment of myofascial pain in the orofacial region with BoNT intervention.…”

Section: Myofascial Painmentioning

confidence: 99%

See 1 more Smart Citation

Mechanism and clinical use of botulinum neurotoxin in head and facial region

et al. 2023

View full text Add to dashboard Cite

Food-borne botulism, derived from the Latin term "botulus," which means "sausage," was first described in the 18 th century. The term was used to define a fatal condition characterized by muscular paralysis resulting in respiratory arrest upon the consumption of raw sausages [1]. Botulinum neurotoxins (BoNTs), which cause botulism, are zinc-dependent metalloproteases produced by an anaerobic, spore-forming, Gram-positive bacterium, Clostridium botulinum, and are classified into seven serotypes (BoNT/A-G) based on their antigenic properties. Apart from the seven distinct BoNTs, an additional serotype has been reported; however, further validation is required for confirmation [2,3].Naturally produced BoNTs are non-covalently associated with one or several non-toxic neurotoxin-associated proteins (NAPs) and form high molecular weight (up to ~900kDa) progenitor toxin complexes (PTCs) at an acidic pH. The PTCs dissociate into BoNTs and NAPs at neutral or alkaline pH. NAPs play a vital role in protecting fragile BoNTs from the harsh environment of the gastrointestinal tract and in facilitating the passage of BoNTs through the intestinal epithelial barrier. BoNT is released from PTCs after absorption from the intestinal epithelial barrier. Free BoNTs are transported to neuromuscular junctions (NMJs) via general circulation, subsequently inhibiting acetylcholine exocytosis and resulting in flaccid paralysis [4]. BoNTs are potent toxins and are currently being extensively researched, not only for their lethality but also for their potential use in therapeutic interventions owing to their safety, efficacy, and long duration of action. BoNT/A and BoNT/B are widely used in clinical practice [5].In the early 19 th century, the first toxin of BoNT (BoNT/A) was identified. Immediately after its discovery, it was widely used for developing biological weapons, given its effects on the nervous system, and it was studied extensively during the Second World War. The therapeutic use of BoNT in the medical field began in the late 19 th century [6,7]. Human use of BoNT was first attempted to treat strabismus (crossed eyes) in 1977 by Scott [6]. Since then, many medical practitioners have used BoNT to treat eyelid twitching and muscle spasms [8]. BoNT/A has also been used to treat neurological J Prosthodont Res. 2023; **(**):

show abstract

Section: Myofascial Painmentioning

confidence: 99%

Section: Myofascial Painmentioning

confidence: 99%

Mechanism and clinical use of botulinum neurotoxin in head and facial region

et al. 2023

View full text Add to dashboard Cite

show abstract

“…2 Contrastingly, 4 studies with a total of 233 participants comparing botulinum toxin A with placebo showed no statistically significant difference in pain intensity. 95 The evidence regarding the value of botulinum toxin injections is inconclusive. 6…”

Section: Nonsurgical Interventional Pain Proceduresmentioning

confidence: 99%

A physiatrist's understanding and application of the current literature on chronic pelvic pain: a narrative review

Ullger

Seko

Shrikhande

et al. 2021

PR9

View full text Add to dashboard Cite

show abstract

“…This is completely different from the acupuncture method as no specific traditional acupuncture points are followed based on the Western neuroanatomy [52]. Reduction of myofascial pain after BTX injection is because of blockade of acetylcholine release at the motor end plates, hence decreasing the muscle spasm [57]. (d) Fascial plane blocks: This is gaining popularity as a promising method since the fascia itself can be a pain generator for many MPS and the blocking of the entire fascia around the muscle produces blockade of somatic nerves and sympathetic fibers that pierces the fascia to reach the muscle.…”

Section: Management Of Myofascial Pain Syndromementioning

confidence: 99%

Interventions for myofascial pain syndrome in cancer pain: recent advances: why, when, where and how

Thottungal

Kumar

Bhaskar

2019

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

Purpose of reviewPain is one of the most feared and most common symptoms of cancer, experienced by 38-85% of patients. Pain in terminally ill cancer patients is a multidimensional experience caused by a diverse array of factors -cancer itself, its treatment or other causes. Studies have shown a high incidence of myofascial pain syndrome (MPS) in patients with cancer and the knowledge of myofascial trigger points (MTrPs) is important to address and manage existing pain, and to prevent the recurrence of pain. This review aims to summarize recent advances in interventions for managing MPS in patients with cancer. Recent findingsDatabase searches were conducted on MEDLINE, CINAHL, and Google Scholar to locate all studies published from inception until April 2019 using the keywords cancer pain, myofascial pain, TrPs with emphasis of any methodological quality that included interventions for MPS. MPS in advanced cancer patients are more commonly observed along with other cancer pains rather than independently with a prevalence of 11.9-48% in those patients diagnosed with cancer of head and neck and breast cancer.

show abstract

Botulinum toxin for myofascial pain syndromes in adults

Cited by 13 publications

References 34 publications

Mechanism and clinical use of botulinum neurotoxin in head and facial region

Mechanism and clinical use of botulinum neurotoxin in head and facial region

A physiatrist's understanding and application of the current literature on chronic pelvic pain: a narrative review

Interventions for myofascial pain syndrome in cancer pain: recent advances: why, when, where and how

Contact Info

Product

Resources

About